Denosumab for the treatment of osteoporosis

McClung, Michael R.

doi:10.1016/j.afos.2017.01.002

Cited by 25 publications

(12 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some potential elements common to the muscle and bone have been highlighted as targets for new therapies, including RANK L inhibition (exclusively antiresorptive action) or IGF-1. Denosumab, a monoclonal antibody used to treat osteoporosis to slow bone breakdown (reducing osteoclastogenesis) can block the receptor activator of nuclear factor-kappa-β ligand (RANK-L)) [ 86 ]. The positive potential of this drug was evaluated in the FREEDOM study [ 87 ], where an increase in BMD was seen in all bone sites with a decrease in fractures in postmenopausal osteoporotic women.…”

Section: Management Of Osteosarcopeniamentioning

confidence: 99%

Osteosarcopenia: A Narrative Review on Clinical Studies

Polito¹,

Barnaba²,

Ciarapica³

et al. 2022

IJMS

View full text Add to dashboard Cite

Osteosarcopenia (OS) is defined by the concurrent presence of osteopenia/osteoporosis and sarcopenia. The pathogenesis and etiology of OS involve genetic, biochemical, mechanical, and lifestyle factors. Moreover, an inadequate nutritional status, such as low intake of protein, vitamin D, and calcium, and a reduction in physical activity are key risk factors for OS. This review aims to increase knowledge about diagnosis, incidence, etiology, and treatment of OS through clinical studies that treat OS as a single disease. Clinical studies show the relationship between OS and the risk of frailty, falls, and fractures and some association with Non-communicable diseases (NCDs) pathologies such as diabetes, obesity, and cardiovascular disease. In some cases, the importance of deepening the related mechanisms is emphasized. Physical exercise with adequate nutrition and nutritional supplementations such as proteins, Vitamin D, or calcium, represent a significant strategy for breaking OS. In addition, pharmacological interventions may confer benefits on muscle and bone health. Both non-pharmacological and pharmacological interventions require additional randomized controlled trials (RCT) in humans to deepen the synergistic effect of exercise, nutritional interventions, and drug compounds in osteosarcopenia.

show abstract

Section: Management Of Osteosarcopeniamentioning

confidence: 99%

Osteosarcopenia: A Narrative Review on Clinical Studies

Polito¹,

Barnaba²,

Ciarapica³

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Besides this, Teriparatide in combination with Denosumab enhanced BMD to a greater extent than either drug alone (Tsai et al, 2013). Research proves that postmenopausal women having low bone mass can be treated more effectively with Denosumab than with oral bisphosphonates (Miller et al, 2016;McClung, 2017).…”

Section: Denosumabmentioning

confidence: 96%

Marine Natural Products: New Avenue in Treatment of Osteoporosis

Chaugule¹,

Indap²,

Chiplunkar

2017

Front. Mar. Sci.

View full text Add to dashboard Cite

Bone metabolism is a physiological process that maintains the skeletal integrity and bone functions. Skeletal integrity is always balanced by two key cell types-bone resorbing osteoclasts and bone-forming osteoblasts. Imbalance between generation and function of osteoclasts and osteoblasts often leads to pathological conditions such as osteoporosis, osteopetrosis, Paget's disease. Osteoporosis is one of the most common age-related diseases characterized by decreased bone mineral density and microarchitectural deterioration. Current therapies are indeed effective in preventing bone loss but are also followed by side effects. Since many years, marine organisms have been considered as a good source of bioactive molecules or compounds with potential pharmaceutical properties. Marine Natural Products (MNPs) derived from various marine resources such as marine cyanobacteria, dinoflagellates, algae, sponges, soft corals, molluscs, fishes, and mangroves had shown profound effect on bone metabolism through inhibiting osteoclastogenesis and up-regulating osteoblastogenesis via modulating RANK/RANKL/OPG pathway. Amongst the pre-clinically investigated MNPs for management of osteoporosis, very few are under phase I clinical trials. This review discusses the currently available pharmacological drugs and there major health concern in osteoporosis treatment. It further gives an insight into various marine resources and marine-derived bioactive products, depicting their mechanism of action, functional role, and how these can be exploited for the treatment of osteoporosis.

show abstract

“…Due to coupling, osteoblasts and consequently bone formation are suppressed as well. However, there is a net increase in bone mineral density leading to effective fracture prevention [ 70 ]. During the first 12 months of the FRAME study, there was a 73% reduction for vertebral fractures ( p < 0.001) and a 36% reduction for clinical fractures ( p = 0.008), while no statistically significant difference was reported for non-vertebral fractures.…”

Section: Monoclonal Antibodies Against Sclerostin In Human Osteopomentioning

confidence: 99%

Osteoporosis Treatment with Anti-Sclerostin Antibodies—Mechanisms of Action and Clinical Application

Rauner

Taipaleenmäki

Tsourdi

et al. 2021

JCM

View full text Add to dashboard Cite

Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased risk of fragility fractures and significant long-term disability. Although both anti-resorptive treatments and osteoanabolic drugs, such as parathyroid hormone analogues, are effective in fracture prevention, limitations exist due to lack of compliance or contraindications to these drugs. Thus, there is a need for novel potent therapies, especially for patients at high fracture risk. Romosozumab is a monoclonal antibody against sclerostin with a dual mode of action. It enhances bone formation and simultaneously suppresses bone resorption, resulting in a large anabolic window. In this opinion-based narrative review, we highlight the role of sclerostin as a critical regulator of bone mass and present human diseases of sclerostin deficiency as well as preclinical models of genetically modified sclerostin expression, which led to the development of anti-sclerostin antibodies. We review clinical studies of romosozumab in terms of bone mass accrual and anti-fracture activity in the setting of postmenopausal and male osteoporosis, present sequential treatment regimens, and discuss its safety profile and possible limitations in its use. Moreover, an outlook comprising future translational applications of anti-sclerostin antibodies in diseases other than osteoporosis is given, highlighting the clinical significance and future scopes of Wnt signaling in these settings.

show abstract

Denosumab for the treatment of osteoporosis

Cited by 25 publications

References 99 publications

Osteosarcopenia: A Narrative Review on Clinical Studies

Osteosarcopenia: A Narrative Review on Clinical Studies

Marine Natural Products: New Avenue in Treatment of Osteoporosis

Osteoporosis Treatment with Anti-Sclerostin Antibodies—Mechanisms of Action and Clinical Application

Contact Info

Product

Resources

About